Oesophageal adenocarcinoma associated with a right‐sided aortic arch

Abstract

date. Radiation is considered an additional risk factor in development of STS with standardized incidence ratio 2.7–18.7 times higher in patients who have received radiotherapy. Chest CT should also be obtained in all newly diagnosed patients as the lungs are the predominant metastatic site. Positron emission tomography/CT is also available, however, there are no guidelines recommending this as a standard follow-up modality. Surgery with negative margins represents the only potentially curative modality for breast angiosarcomas. For patients with radiation-associated secondary breast sarcomas, the role of adjuvant radiotherapy is unclear, and the decision to pursue re-irradiation must be individualized. The amount of additional radiotherapy that may be given in a previously irradiated field is limited, and toxicities are greater. Paclitaxel and gemcitabinetaxane, as well as propanolol and vinblastine metronomic chemotherapy have been demonstrated to have promising effects for primary or recurrent angiosarcoma, however, further trials are needed. RAAS of the irradiated site is a rare, but lethal complication of breast cancer radiotherapy. Early recognition and knowledge of treatment modalities is imperative for successful surgical management. Patients should be thoroughly informed of this potential complication prior to undertaking radiotherapy and be aware of the signs and symptoms of this condition.